Profile data is unavailable for this security.
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
- Revenue in USD (TTM)26.87m
- Net income in USD-149.32m
- Incorporated2017
- Employees166.00
- LocationZentalis Pharmaceuticals Inc10275 Science Center Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 263-4333
- Fax+1 (302) 655-5049
- Websitehttps://www.zentalis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | 6.65m | -136.32m | 159.28m | 161.00 | -- | 0.7628 | -- | 23.97 | -1.15 | -1.15 | 0.056 | 1.80 | 0.0175 | -- | 2.58 | 41,279.50 | -35.89 | -32.10 | -39.80 | -36.05 | -- | -- | -2,051.08 | -414.22 | -- | -- | 0.00 | -- | -51.24 | -26.71 | 26.82 | -- | 3.83 | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 160.51m | 21.00 | -- | 2.01 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Jyong Biotech Ltd | 0.00 | -2.95m | 162.70m | 29.00 | -- | -- | -- | -- | -0.0397 | -0.0397 | 0.00 | -0.3027 | 0.00 | -- | -- | 0.00 | -13.35 | -- | -127.41 | -- | -- | -- | -- | -- | -- | -1.96 | 2.79 | -- | -- | -- | 31.39 | -- | -- | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 164.50m | 147.00 | -- | 1.16 | -- | 17.70 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 165.34m | 131.00 | -- | 2.54 | -- | 15.75 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| MDxHealth SA | 103.07m | -31.43m | 165.82m | 312.00 | -- | -- | -- | 1.61 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 167.70m | 105.00 | -- | -- | -- | 139.75 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 171.96m | 166.00 | -- | 0.68 | -- | 6.40 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Canton Strategic Holdings Inc | 0.00 | -10.32m | 174.31m | 2.00 | -- | 5.41 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 176.18m | 6.00 | -- | 4.21 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 180.05m | 105.00 | -- | 6.42 | -- | 1.21 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Insight Molecular Diagnostics Inc | 4.40m | -60.78m | 180.68m | 46.00 | -- | -- | -- | 41.04 | -2.83 | -2.83 | 0.1643 | -0.3213 | 0.0771 | 5.67 | 18.85 | 95,695.65 | -106.49 | -41.57 | -124.80 | -46.86 | 54.73 | 24.70 | -1,380.69 | -2,290.77 | 2.73 | -171.82 | -- | -- | 25.15 | -- | -136.17 | -- | -10.88 | -- |
| Nkarta Inc | 0.00 | -102.61m | 182.55m | 105.00 | -- | 0.5402 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 182.77m | 14.00 | -- | 1.53 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 183.80m | 8.00 | -- | 18.86 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
| SAB Biotherapeutics Inc | 114.70k | -21.37m | 185.19m | 63.00 | -- | 1.12 | 8.43 | 1,614.57 | -2.81 | -2.81 | 0.0043 | 3.48 | 0.001 | -- | 0.3492 | 1,820.64 | 15.80 | -- | 17.22 | -- | -- | -- | 16,338.04 | -- | -- | -- | 0.0197 | -- | -40.94 | -- | 19.17 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Zentalis Pharmaceuticals Inc's reporting currency: US Dollar USD
25.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2025 | 2.88m | 3.99% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 2.85m | 3.94% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.55m | 3.53% |
| Citadel Advisors LLCas of 31 Dec 2025 | 1.68m | 2.32% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 1.66m | 2.30% |
| Two Sigma Advisers LPas of 31 Dec 2025 | 1.48m | 2.05% |
| Two Sigma Investments LPas of 31 Dec 2025 | 1.47m | 2.04% |
| Opaleye Management, Inc.as of 31 Dec 2025 | 1.40m | 1.94% |
| Ishara Investments LPas of 31 Dec 2025 | 1.32m | 1.83% |
| BofA Securities, Inc.as of 31 Dec 2025 | 1.25m | 1.73% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
